Certara Inc (CERT)

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItJune 16, 2026 8:45 AM
PR Newswire (US) Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /PRNewswire/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually building these systems: in biology, the model may be the least durable part of the equation. Models improve, get copied, and get commoditized. What is hard — and potentially far more valuable — is the connected, trustworthy biological knowledge the model has to reason over in the first place. Feed even a brilliant model fragmented, contradictory data and it will, in the words of one industry executive, confidently get it wrong. That debate moves to center stage on June 15, 2026, when MindWalk Holdings Corp. (NASDAQ: HYFT) joins a virtual investor panel hosted by research firm Jones — alongside generative-biology company Absci (NASDAQ: ABSI) and a leading AI compute provider — titled "Partnering to Power the New Era of Drug Discovery." The panel is a small event, but it sits on top of one of the most consequential questions in biotech: as the industry pours capital into AI, what is the part that actually compounds in value? MindWalk's answer — and the trajectory of the broader field — is worth understanding now, because it reframes where the durable advantages in AI-driven medicine may ultimately lie.Why AI Drug Discovery Hit a Wall — and What ChangedThe promise of applying AI to drug discovery has always been intoxicating: compress the decade-plus, billion-dollar odyssey of finding and validating a new medicine into something faster, cheaper, and more likely to succeed. The early wave of "AI-first" biotechs raised enormous sums on that promise. But the field ran into a hard truth that has little to do with algorithms. Biological data is a mess. It is scattered across incompatible files, formats, instruments, lab notebooks, and decades of literature; it is riddled with gaps and contradictions; and the relationships that matter most — how a sequence maps to a structure, a function, a mechanism, a disease — are often implicit rather than recorded. A model trained or prompted on that fragmented foundation can produce fluent, confident answers that are simply wrong, a failure mode the field has come to call hallucination.In consumer applications, a hallucinating chatbot is an annoyance. In drug discovery, it is a multimillion-dollar wrong turn, sending scientists down a path toward a target or molecule that was never viable. As the industry now races to deploy not just static AI models but autonomous "agentic" systems — AI that can plan and execute multi-step research workflows with limited human supervision — the cost of bad underlying data multiplies. An agent acting on fragmented biology does not just give one wrong answer; it compounds the error across an entire chain of decisions. That escalating risk is exactly why attention is shifting from the models themselves to the integrity of the biological foundation they operate on.MindWalk's Bet: Own the Context Layer, Not the ModelMindWalk — a company that rebranded in 2025 from its prior identity as ImmunoPrecise Antibodies, unifying its operations and adopting the Nasdaq ticker HYFT — has built its entire strategy around that shift. Rather than competing to build the flashiest model, the company positions its durable asset as the layer underneath: a biological "context layer" that connects and enriches data before any model reasons over it. Its proprietary HYFT® Technology, refined over roughly two decades of curation, is described as a continuously evolving biological representation spanning 660 million biological patterns and 25 billion relationships — a kind of connective tissue that links sequences, structures, functions, mechanisms, pathways, evidence, and literature into a single queryable foundation.On top of that foundation sit two products the company has brought to market. ReefIQ™, launched in June 2026, is pitched as the biological context layer that sits between a client's fragmented discovery data and its AI reasoning workflows — reconnecting the pieces before the AI acts. LensAI™ is the reasoning and application layer used for target discovery, candidate diligence, and portfolio decision support, and increasingly to host the agentic workflows pharma is racing to adopt. The company's central thesis, which CEO Dr. Jennifer Bath is expected to articulate on the Jones panel, is that because its predictions are grounded in what evolution has already conserved — the functional patterns that have survived across biology — rather than in raw statistical correlation, the system is designed to keep both models and agents from hallucinating in the highest-consequence workflows. Bath has framed the convergence she sees as "biology, context, and compute."Importantly, this is not purely conceptual. MindWalk reported that its largest enterprise AI client signed a one-year LensAI platform contract — the first contracted, recurring platform-revenue agreement in the company's history — and that the structure is one it intends to scale across its client base. For its fiscal third quarter ended January 31, 2026, the company reported revenue of $4.2 million (in Canadian dollars), up 52% year-over-year and a third consecutive quarter of year-over-year growth, with U.S. revenue doubling. The company also reported preclinical dengue data that, by its account, supported a computational prediction its platform generated before any animal was immunized — an early, real-world validation of the approach.The Field Around MindWalkMindWalk is one expression of a sector that has matured well beyond the first hype cycle, and looking at how a few public peers are positioned helps frame both the opportunity and where MindWalk's niche sits within it. Each of these companies attacks the AI-drug-discovery problem from a different layer of the stack.Absci Corporation (NASDAQ: ABSI) — MindWalk's fellow panelist — represents the generative-design frontier. The company uses generative AI models paired with an integrated wet lab to design therapeutic antibodies essentially from scratch, conditioning its models on a target's structure and then validating proposals through high-throughput experiments. Absci became clinical-stage with an AI-designed antibody entering a Phase 1 trial, making it a closely watched proof point for whether generative design can produce real drugs. It illustrates the "design" layer of the field — complementary to the data-foundation layer MindWalk emphasizes.Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is among the largest and best-known "AI-first" drug discovery platforms, having industrialized the generation of biological data through massive automated experimentation and paired it with machine learning to identify drug candidates. With collaborations involving major pharmaceutical companies and its own clinical-stage pipeline, Recursion represents the scaled, full-stack ambition of the sector — building both the data engine and the drug pipeline — and the patient capital that strategy requires.Schrödinger, Inc. (NASDAQ: SDGR) approaches the problem from a different intellectual tradition: physics-based computational chemistry. Its software platform simulates how molecules behave at a fundamental level to predict which candidates are worth pursuing, and it both licenses that software to the industry and advances its own pipeline. Schrödinger illustrates the established, software-led end of the field — a reminder that "computational drug discovery" predates the current AI wave and that different modeling philosophies coexist and compete.Certara, Inc. (NASDAQ: CERT) rounds out the group as the infrastructure-and-decision-support comparison closest in spirit to MindWalk's positioning. A leader in biosimulation and model-informed drug development, Certara provides software and AI-powered services used across the drug-development lifecycle, including in regulatory submissions. As one of the more established, revenue-generating names in the space, it demonstrates that there is a durable, infrastructure-layer business in AI-enabled drug development — the same category MindWalk is targeting with its context layer, albeit at a far larger and more mature scale. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they differ widely in approach, size, and stage, and MindWalk is among the smaller, earlier-stage names. References to Absci, Jones, and the other panelists describe the event only and do not imply any endorsement or commercial relationship.The Investment Case — and the RisksThe bull case for the context-layer thesis is conceptually elegant. If models are destined to commoditize — and the pace at which capable AI models now proliferate suggests they might — then the enduring value in AI drug discovery accrues to whoever owns the trusted, connected biological foundation that every model and agent must rely on. A context layer, in that telling, becomes infrastructure: something pharma rents rather than rebuilds, with recurring revenue and compounding value as more data and more programs run through it. MindWalk's first recurring platform contract and its growing revenue are early evidence that customers may be willing to pay for exactly that.The risks, however, are substantial and should not be minimized. MindWalk is a small-cap company still posting operating losses as it transitions from a legacy wet-lab services business toward a scalable platform model. Its revenue, while growing, is modest in absolute terms, and the company depends on converting engagement into contracted, recurring arrangements that have only just begun. It relies on third-party compute and cloud providers, faces intense competition from larger and better-funded players, and operates in a field where adoption of bio-native and agentic AI could prove slower than hoped. As with any clinical- or platform-stage life-sciences company, there is no certainty that the capabilities described will translate into commercial success, and forward-looking claims about the technology remain just that — forward-looking.A Sector Finding Its Real FoundationWhat makes this moment interesting is not any single company or any single panel. It is that the AI-drug-discovery field appears to be maturing past its first, model-obsessed phase into a more sophisticated understanding of where value actually lives. The lesson emerging from the first wave — that pointing powerful AI at messy biology produces confident nonsense — has pushed serious players toward the unglamorous but essential work of connecting and grounding biological knowledge. Whether the durable advantage ultimately sits in generative design, industrialized data generation, physics-based simulation, or a connected context layer is precisely the question a panel like the one on June 15 exists to debate.MindWalk has placed a clear, focused bet on the context layer — that in the age of agentic AI, the biology has to be connected and trustworthy before a model ever acts on it, and that owning that foundation is the durable prize. It is an early-stage bet, with real execution and financing risk, and the market has yet to render its verdict. But the trajectory of the field is unmistakable: the conversation has moved from "whose model is biggest" toward "whose biology is most trustworthy," and the companies building that foundation are positioning themselves at what may prove to be the most defensible layer of the entire AI-medicine stack. For investors trying to understand where the next decade of drug discovery is headed, that shift is the story worth watching.SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVESEagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.Explore Eagle Eye free (for now) at https://Eagle-Eye.devCONTACT:Equity Insiderinfo @therooster-2873SOURCES:[1] MindWalk Holdings Corp. — "MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel…" (Business Wire, June 12, 2026; primary source for the panel, HYFT/ReefIQ/LensAI platform, Bath quote, 660M patterns / 25B relationships):
https://finance.yahoo.com/sectors/healthcare/articles/mindwalk-nasdaq-hyft-ceo-dr-130000157.html[2] MindWalk Holdings Corp. — "Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery" (Business Wire, June 10, 2026; ReefIQ context-layer detail):
https://www.businesswire.com/news/home/20260610294167/en/MindWalk-Holdings-Corp.-NASDAQ-HYFT-Launches-ReefIQ-a-Biological-Context-Layer-for-AI-Drug-Discovery[3] MindWalk Holdings Corp. — "Reports Q3 Fiscal 2026 Financial Results" (Business Wire, March 12, 2026; $4.2M revenue +52% YoY, first recurring LensAI contract, subsidiaries):
https://www.businesswire.com/news/home/20260312858299/en/MindWalk-Holdings-Corp.-Reports-Q3-Fiscal-2026-Financial-Results[4] MindWalk Holdings Corp. — "ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to 'HYFT'" (Business Wire, Sept 3, 2025; rebrand, platform business-model shift):
https://www.businesswire.com/news/home/20250903938726/en/ImmunoPrecise-Rebrands-as-MindWalk-Announces-NASDAQ-Ticker-Change-to-HYFT[5] BioPharmaTrend — "Publicly Traded AI-driven Drug Discovery Companies" and related sector coverage (peer context: Absci, Recursion, Schrödinger, Certara):
https://www.biopharmatrend.com/artificial-intelligence/recent-ipos-among-ai-driven-platforms-for-drug-discovery-and-biotech-601/DISCLAIMER:Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by Equity Insider on behalf of MIQ. MIQ has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group ("CDMG"). This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. MIQ does not own shares of MindWalk Holdings Corp. but reserves the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice. There may be 3rd parties who may have shares of MindWalk Holdings Corp., and may liquidate their shares which could have a negative effect on the price of the stock. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of MindWalk Holdings Corp. by CDMG; this is a digital media distribution.While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Comparisons to other companies referenced in this publication are for contextual and illustrative purposes only and do not imply any partnership, endorsement, affiliation, or comparable financial performance. References to the Jones AI Day panel, Absci, and other panelists describe the event only and do not imply any endorsement, sponsorship, partnership, or commercial relationship. Forward-looking statements regarding technology, platform adoption, recurring revenue, clinical and preclinical outcomes, and market trends are subject to risks and uncertainties, and actual results may differ materially. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content to download multimedia:https://www.prnewswire.com/news-releases/the-quiet-bottleneck-in-ai-drug-discovery-isnt-the-model--its-the-biology-underneath-it-302800965.html Original: The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

May 026 bottom @ 4.5 ..Need to get back in channel of 8 - 10
having lost almost 50m shares in the last 10 sessions

Certara (CERT) Shares Slide After Weak Full-Year Guidance Overshadows Revenue BeatMay 11, 2026 10:17 AM
IH Market News Certara, Inc. (NASDAQ:CERT) shares plunged more than 12% in premarket trading on Monday after the company issued weaker-than-expected full-year guidance despite reporting first-quarter revenue slightly ahead of forecasts.The drug development software and services company posted adjusted earnings per share of $0.09, missing analyst expectations of $0.11 per share. Revenue Edges Higher but Profitability Softens First-quarter revenue totaled $106.9 million, narrowly topping the consensus estimate of $106.1 million and increasing 1% from $106.0 million in the same period last year.Software revenue rose 7% year-over-year to $49.7 million, while services revenue declined 4% to $57.2 million.Adjusted EBITDA fell 9% to $31.7 million from $34.8 million in the prior-year quarter. Investors React to Lower-Than-Expected Outlook The company’s updated 2026 guidance disappointed investors, particularly on earnings expectations.Certara forecast full-year adjusted earnings per share in a range of $0.35 to $0.41, well below analyst consensus estimates of $0.45 per share.The midpoint of the guidance range, $0.38, sits roughly 16% below market expectations.The company also projected full-year revenue of $395 million to $405 million, with the midpoint of $400 million trailing the Wall Street consensus forecast of $425 million. Divestiture and Strategic Reorganization Underway Certara said the updated outlook reflects the completed sale of its Regulatory and Medical Writing business to Veristat.The transaction included $85 million in cash upfront, with the potential for up to an additional $50 million in future consideration.“I am pleased with the progress we made in my first quarter at Certara,” said Chief Executive Officer Jon Resnick. “We are taking decisive steps to sharpen our execution and position Certara for long-term growth, including divesting our Medical Writing business, reorganizing around two focused growth areas, and accelerating our enterprise-wide AI program.”Chief Financial Officer John Gallagher said that excluding the divested business, the company expects full-year revenue growth of between 0% and 4%.Certara also forecast a full-year adjusted EBITDA margin in the range of 30% to 32%.Certara stock price Original: Certara (CERT) Shares Slide After Weak Full-Year Guidance Overshadows Revenue Beat

Altasciences et Certara annoncent un partenariat stratégique visant à accélérer le développement de médicaments en phase précoceMay 7, 2026 8:16 PM
Business Wire Altasciences , une organisation proposant des solutions de développement de médicaments pleinement intégrées, et Certara (Nasdaq : CERT), leader mondial du développement de médicaments fondé sur des modèles (MIDD), ont annoncé aujourd'hui la conclusion d'un partenariat stratégique visant à accélérer les programmes de développement en phase précoce. Moins de la moitié des candidats médicaments précliniques parviennent à passer le cap des premiers essais cliniques chez l'humain. Les échecs sont principalement dus à la toxicité, à une pharmacocinétique défavorable, à un manque d'efficacité et aux difficultés rencontrées pour transposer à l'homme des résultats obtenus sur des animaux. Bon nombre de ces risques peuvent être atténués grâce à une approche de développement de médicaments pleinement intégrée et fondée sur des modèles. S'appuyant sur la plateforme d'accélération d'Altasciences, l’intégration des services de développement stratégique de médicaments et de la technologie de biosimulation de Certara permet aux sponsors d’établir plus rapidement la preuve de concept, de concevoir des études plus efficaces et de prendre des décisions éclairées quant au lancement ou à l'abandon de l'essai en plus grande confiance. En intégrant les données de modélisation et les workflows numériques directement à l’exécution du développement, les plans d’étude sont optimisés, les stratégies posologiques évoluent et les programmes sont mieux intégrés aux services non cliniques, cliniques, bioanalytiques et de production. « Chez Altasciences, nous aidons déjà les sponsors à passer rapidement de la première évaluation de sécurité à la validation de principe de manière rapide et précise », a déclaré Marie-Hélène Raigneau, CEO d’Altasciences. « En intégrant les capacités de modélisation de Certara à notre plateforme, nous pouvons éclairer davantage les décisions critiques, plus tôt et avec une plus grande assurance. Cette collaboration vise à réduire l’incertitude aux moments les plus importants. » Ce partenariat arrive à point nommé, alors que la FDA continue de promouvoir de nouvelles orientations en faveur d'approches de développement de médicaments plus adaptatives, fondées sur les données et en temps réel : des capacités que les modèles d'exécution MIDD intégrés peuvent parfaitement fournir. « Ce partenariat ouvre de nouvelles perspectives pour faciliter les décisions relatives au développement précoce chez les sponsors de biotechnologies et leurs investisseurs », a déclaré Jon Resnick, CEO de Certara. « En intégrant la modélisation et la simulation directement à l'exécution, nous permettons une prise de décision plus rapide et plus éclairée, ce qui, en fin de compte, profite aux patients. » Ensemble, Altasciences et Certara font progresser une approche du développement précoce de médicaments, axée sur la modélisation, entièrement intégrée et économe en ressources qui accélère le processus de validation de principe pour les innovateurs en biotechnologie, les investisseurs et les laboratoires pharmaceutiques du monde entier. À propos d'Altasciences Altasciences est une société de solutions de développement pharmaceutique intégrées qui propose aux entreprises pharmaceutiques et biotechnologiques une approche éprouvée et flexible pour leurs programmes d'études précliniques et cliniques, notamment la formulation, la fabrication et les services analytiques. Depuis plus de 30 ans, Altasciences collabore avec les sponsors pour les aider à prendre des décisions éclairées, plus rapides et plus complètes en matière de développement précoce de médicaments. Les solutions intégrées et complètes d'Altasciences comprennent les essais de sécurité précliniques, la pharmacologie clinique et la validation de principe, la bioanalyse, la gestion de programmes, la rédaction médicale, la biostatistique et la gestion des données. Elles sont entièrement personnalisables selon les besoins spécifiques des sponsors. Altasciences aide les sponsors à mettre plus rapidement des médicaments plus efficaces à la disposition des patients qui en ont besoin. À propos de Certara Certara accélère le développement de médicaments grâce à des logiciels, des technologies et des services de modélisation, transformant ainsi les méthodes traditionnelles de découverte et de développement pharmaceutiques. Parmi ses clients figurent plus de 2 600 entreprises biopharmaceutiques, institutions universitaires et organismes de réglementation répartis dans 70 pays. Rendez-vous sur www.certara.com. Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence. Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260507024608/fr/ Julie-Ann Cabana
Altasciences
media@altasciences.com Original: Altasciences et Certara annoncent un partenariat stratégique visant à accélérer le développement de médicaments en phase précoce

Altasciences und Certara kündigen strategische Partnerschaft zur Beschleunigung der frühen Phase der Arzneimittelentwicklung anMay 7, 2026 8:17 PM
Business Wire Altasciences , ein vollständig integriertes Unternehmen für Arzneimittelentwicklungslösungen, und Certara (Nasdaq: CERT),, ein Weltmarktführer im Bereich modellgestützte Arzneimittelentwicklung (Model-Informed Drug Development, MIDD), haben heute eine strategische Partnerschaft bekannt gegeben, in deren Rahmen sie Entwicklungsprogramme in der Frühphase beschleunigen wollen. Weniger als die Hälfte der präklinischen Wirkstoffkandidaten schafft es erfolgreich bis zu ersten Studien am Menschen. Ursachen für das Scheitern sind Toxizität, ungünstige Pharmakokinetik, mangelnde Wirksamkeit sowie Schwierigkeiten bei der Übertragung der Ergebnisse aus Tierversuchen auf den Menschen. Viele dieser Risiken können durch einen vollständig integrierten, modellgestützten Ansatz in der Wirkstoffentwicklung minimiert werden. Die auf der Acceleration Platform von Altasciences aufbauende Integration der strategischen Dienstleistungen zur Arzneimittelentwicklung und der Biosimulationstechnologie von Certara ermöglicht es Auftraggebern, früher einen Wirkmechanismusnachweis zu erbringen, effizientere Studiendesigns zu entwerfen und fundierte Go/No-Go-Entscheidungen mit größerer Sicherheit zu treffen. Durch die direkteEinbindung von Modellierungserkenntnissen und digitalen Arbeitsabläufen in die Entwicklungsdurchführung können Studiendesigns optimiert, Dosierungsstrategien verfeinert und Programme nahtloser über nichtklinische, klinische, bioanalytische und herstellungstechnische Dienstleistungen hinweg integriert werden. „Bei Altasciences unterstützen wir Auftraggeber bereits heute dabei, schnell und präzise von der ersten Sicherheitsbewertung bis hin zum Konzeptnachweis zu gelangen“, so Marie-Hélène Raigneau, CEO von Altasciences. „Durch die Einbindung der Modellierungsfunktionen von Certara in unsere Plattform können wir noch früher und mit größerer Sicherheit Informationen für wichtige Entscheidungen bereitstellen. Ziel dieser Zusammenarbeit ist es, Unsicherheiten in den entscheidenden Momenten zu verringern.“ Die Partnerschaft wird zu einem günstigen Zeitpunkt eingegangen, da die FDA weiter neue Leitlinien zur Förderung adaptiverer, datengestützter und in Echtzeit erfolgender Ansätze in der Arzneimittelentwicklung vorantreibt – Fähigkeiten, für deren Umsetzung integrierte MIDD-Ausführungsmodelle bestens aufgestellt sind. „Diese Partnerschaft erschließt neue Möglichkeiten zur Verbesserung früher Entwicklungsentscheidungen für Biotech-Auftraggeber und ihre Investoren“, so Jon Resnick, CEO von Certara. „Indem wir Modellierung und Simulation direkt in die Umsetzung einbetten, ermöglichen wir eine schnellere und fundiertere Entscheidungsfindung, von der letzten Endes die Patienten profitieren.“ Altasciences und Certara treiben gemeinsam einen modellorientierten, vollständig integrierten und ressourceneffizienten Ansatz für die frühe Arzneimittelentwicklung voran, der den Weg zum Konzeptnachweis für Biotech-Innovatoren, Investoren und Pharmaunternehmen weltweit beschleunigt. Über Altasciences Altasciences ist ein Unternehmen für integrierte Arzneimittelentwicklungslösungen, das Pharma- und Biotechnologieunternehmen einen bewährten, flexiblen Ansatz für präklinische und klinische Studienprogramme bietet, einschließlich Formulierungs-, Herstellungs- und Analysedienstleistungen. Altasciences arbeitet seit über 30 Jahren mit Auftraggebern zusammen, um fundierte, schnellere und umfassendere Entscheidungen in der frühen Phase der Arzneimittelentwicklung zu unterstützen. Die integrierten Full-Service-Lösungen des Unternehmens umfassen präklinische Sicherheitsprüfungen, klinische Pharmakologie und Konzeptnachweis, Bioanalytik, Programmmanagement, Medical Writing, Biostatistik und Datenmanagement, die alle an die spezifischen Anforderungen der jeweiligen Auftraggeber angepasst werden können. Altasciences unterstützt seine Auftraggeber bei der schnelleren Bereitstellung besserer Medikamente für die Menschen, die sie benötigen. Über Certara Certara beschleunigt die Entwicklung von Arzneimitteln mithilfe von Biosimulationssoftware, Technologie und Dienstleistungen, um die traditionelle Arzneimittelforschung und -entwicklung zu transformieren. Zu den Kunden von Certara zählen mehr als 2.600 biopharmazeutische Unternehmen, akademische Einrichtungen und Zulassungsbehörden in 70 Ländern. Besuchen Sie uns unter www.certara.com. Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab. Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260507437848/de/ Julie-Ann Cabana
Altasciences
media@altasciences.com Original: Altasciences und Certara kündigen strategische Partnerschaft zur Beschleunigung der frühen Phase der Arzneimittelentwicklung an